Xilio Therapeutics (XLO) Non Operating Interest Expenses (2020 - 2022)

Xilio Therapeutics has disclosed Non Operating Interest Expenses across 3 years of filings, most recently posting $129000.0 for Q1 2022.

• In Q1 2022, Non Operating Interest Expenses fell 12.24% year-over-year to $129000.0; the TTM figure through Mar 2022 stood at $740000.0 (changed N/A YoY), while the FY2021 annual figure was $756000.0, up 15.24% from the prior year.
• Non Operating Interest Expenses came in at $129000.0 for Q1 2022 at Xilio Therapeutics, down from $174000.0 in the prior quarter.
• In the past five years, Non Operating Interest Expenses ranged from a high of $290000.0 in Q3 2021 to a low of $129000.0 in Q1 2022.
• Average Non Operating Interest Expenses over 3 years is $185500.0, with a median of $175500.0 recorded in 2020.
• Year-over-year, Non Operating Interest Expenses soared 47.96% in 2021 and slipped 12.24% in 2022.
• Over 3 years, Non Operating Interest Expenses stood at $177000.0 in 2020, then retreated by 1.69% to $174000.0 in 2021, then dropped by 25.86% to $129000.0 in 2022.
• Per Business Quant data, the three most recent Non Operating Interest Expenses figures were $129000.0 in Q1 2022, $174000.0 in Q4 2021, and $290000.0 in Q3 2021.